Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ultragenyx Pharmaceutical ( (RARE) ) has provided an announcement.
On July 9, 2025, Ultragenyx Pharmaceutical announced that the Phase 3 portion of the Orbit study for UX143 (setrusumab) in patients with osteogenesis imperfecta is progressing as planned, with final analysis expected by the end of the year. The Data Monitoring Committee confirmed the drug’s acceptable safety profile, allowing the study to continue, with final analyses to be conducted after 18 months of therapy, indicating potential positive implications for the company’s operations and stakeholders.
The most recent analyst rating on (RARE) stock is a Buy with a $81.00 price target. To see the full list of analyst forecasts on Ultragenyx Pharmaceutical stock, see the RARE Stock Forecast page.
Spark’s Take on RARE Stock
According to Spark, TipRanks’ AI Analyst, RARE is a Neutral.
Ultragenyx Pharmaceutical’s overall stock score is driven by strong revenue growth and positive developments in clinical trials, as highlighted in the earnings call and recent FDA designation. However, significant profitability challenges and negative cash flows weigh heavily on the score. Technical indicators suggest short-term bullish momentum, but valuation concerns due to negative earnings limit the stock’s appeal. The company’s strategic focus on achieving profitability by 2027 provides a long-term growth outlook.
To see Spark’s full report on RARE stock, click here.
More about Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc. operates in the biotechnology industry, focusing on developing novel products for rare and ultra-rare genetic diseases. The company is known for its commitment to advancing therapies that address unmet medical needs in these specialized markets.
Average Trading Volume: 1,055,128
Technical Sentiment Signal: Sell
Current Market Cap: $3.74B
For a thorough assessment of RARE stock, go to TipRanks’ Stock Analysis page.